
In today’s briefing:
- Basilea Pharmaceutica — Innovation meets execution in anti-infectives
- Cybin, Inc: CYB003 Vs. GH001 – Duration, Durability and Protocol Execution
- Telix Pharmaceuticals (TLX AU): Why Negative Impact of SEC Probe Is A Temporary Setback

Basilea Pharmaceutica — Innovation meets execution in anti-infectives
We revisit our investment case for Basilea Pharmaceutica as it is navigating a period of heightened business activity, with the US launch of Zevtera and the anticipated second Phase III trial for lead drug designate fosmanogepix. We believe that Basilea’s anti-infectives-focused business model remains resilient amid increased macroeconomic uncertainty, with the building blocks in place for sustained growth. Following a rewarding 2024 (revenues up c 32% y-o-y to CHF208.5m), we continue to expect Cresemba to spearhead growth but see further upside from Zevtera sales in the US. A strong cash balance (CHF124.6m) and R&D backing from BARDA (another $39m committed in July) de-risks development plans in the medium term. Trading at an FY25e P/E ratio of 11x (vs the c 20x industry average), the stock is priced attractively, in our view. We raise our valuation to CHF1,291.4m or CHF105.2 per share (from CHF1,155.5m or CHF95.3/share).
Cybin, Inc: CYB003 Vs. GH001 – Duration, Durability and Protocol Execution
- GH Research (NASDAQ:GHRS) releases GH001 final Phase 2b OLE data.
- The final data from GH Research’s six-month open-label extension (OLE) study of its lead fast-onset and short-acting 5-MeO-DMT monotherapy candidate GH001 in treating treatment-resistant depression (TRD) has been released with a headline remission rate of 73% at six months.
- The results did not disclose the changes in MADRS from baseline, but in any event the remission data appears to represent a good outcome. But let’s examine the results further.
Telix Pharmaceuticals (TLX AU): Why Negative Impact of SEC Probe Is A Temporary Setback
- Telix Pharmaceuticals (TLX AU) received a subpoena from the SEC seeking various documents and information primarily relating to the company’s disclosures regarding the development of prostate cancer therapeutic candidates.
- Telix is in the process of responding to the information request. The company has elected to notify the Australian Securities and Investments Commission of the SEC’s information request.
- SEC subpoena will not affect the normal business operation of Telix. While the matter is ongoing, Telix will continue clinical development programs for its prostate cancer therapy candidates.